Downstream signaling pathways, including the PI3K-Akt-mTOR pathway, the Ras-Raf-MEK-ERK pathway, and the IGF-IR pathway, can become abnormally and persistently activated, enabling tumor cells to evade trastuzumab's effects and develop drug resistance100,101. This evidence concerns the gene MAP2K7 and neoplasm.